Despite the fact that the majority of type 2 diabetic patients, when starting PPARγ agonist treatment, are middle-aged without lung problems, detailed investigation into the long-term effects of administration of exogenous PPARγ agonists on the healthy lungs of middle-aged individuals is still missing. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.